Description: IBEX Technologies Inc., through its subsidiaries, IBEX Pharmaceuticals Inc. and BioResearch Products Inc., manufactures and markets enzymes for biomedical use. The Company also manufactures and markets a series of arthritis assays, which enable the study of both the synthesis and degradation of cartilage components. It operates through the production and sale of diagnostic products segment. Its products include IB-C2C-HUSA, C2C Assay, CPII Assay, C1-2C Assay and CS-846 Assay. It provides various individual collagen associated antibodies, such as Ab1320-Rabbit Polyclonal Antibody; Type IX Collagen Antibody, and C1-2C Antibody (Col 2 3/4C short Antibody). Its diagnostic microtiter enzyme-linked immunosorbent assays include C2C-Collagen Type II Cleavage Assay; IB-C2C-HUSA-IBEX C2C Human Urine Sandwich Assay; C1,2C-Collagen Type I and II Cleavage Assay (Col 2 3/4C short antibody); CPII-Procollagen Type II C-Propeptide Assay, and CS846-Aggrecan Chondroitin Sulfate 846 Epitope Assay.
Home Page: www.ibex.ca
IBT Technical Analysis
5485 Rue Pare
Montreal,
QC
H4P 1P7
Canada
Phone:
514 344 4004
Officers
| Name | Title |
|---|---|
| Mr. Paul Baehr | Pres, CEO & Chairman |
| Belinda Franco C.A., CPA | CFO, VP of Fin. & Admin. and Sec. |
| Mahendra Kumar Pallapothu | VP of Operations |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 13.1667 |
| Price-to-Book MRQ: | 1.2205 |
| Price-to-Sales TTM: | 1.5701 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |